APAC IPOs & Placements, Aequitas Research

Nicholas Tan

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Event-Driven

<ul>
<li>Cosette signed a binding agreement to acquire <a href="https://www.smartkarma.com/entities/mayne-pharma-group-ltd" target="_blank" data-smartkarma-citation="entities:757:1" rel="noopener">Mayne Pharma (MYX AU)</a>  for $7.40 per share.</li>
<li>Cosette predictably got cold feet and is attempting to terminate the deal, invoking the deal’s material adverse clause.</li>
<li>Moreover, Cosette has repeatedly failed to quantify its allegations. The extant stock price implies a less than 30% chance of deal closure in spite of having zero precedence for support.</li>
</ul>


Cosette signed a binding agreement to acquire Mayne Pharma (MYX AU)  for $7.40 per share.
Cosette predictably got cold feet and is attempting to terminate the deal, invoking the deal’s material adverse clause.
Moreover, Cosette has repeatedly failed to quantify its allegations. The extant stock price implies a less than 30% chance of deal closure in spite of having zero precedence for support.


Mayne Pharma: No Precedence for a Deal Termination